公开(公告)号：US20060223826A1

公开(公告)日：2006-10-05

申请号：US10534725

申请日：2003-11-18

Applicant: Hidenori Abe ,  Shinichiro Matsunaga ,  Shiro Takekawa ,  Masanori Watanabe

Inventor： Hidenori Abe ,  Shinichiro Matsunaga ,  Shiro Takekawa ,  Masanori Watanabe

IPC: A61K31/496 ,  A61K31/454 ,  C07D403/02

CPC classification number: C07D401/12 ,  C07D209/20 ,  C07D209/42 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04

Abstract: The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

Abstract translation: 本发明提供式（I）的化合物，其中环A表示任选具有取代基的芳环; B，Y和Ya是相同或不同的，每个代表一个债券等; R 1和R 2相同或不同，各自表示氢原子等; R 3表示氢原子等; R 4和R 5相同或不同，各自表示氢等; R 6表示任选具有取代基的吲哚基; Z和Za相同或不同，各自表示氢原子等; 或其盐或其前药，具有生长抑素受体结合抑制活性，并且可用于预防和/或治疗与生长抑素相关的疾病。

公开(公告)号：US20060100261A1

公开(公告)日：2006-05-11

申请号：US10526507

申请日：2003-09-04

Applicant: Kazumasa Hamamura ,  Shigekazu Sasaki ,  Yuichiro Amano ,  Junichi Sakamoto ,  Kohji Fukatsu

Inventor： Kazumasa Hamamura ,  Shigekazu Sasaki ,  Yuichiro Amano ,  Junichi Sakamoto ,  Kohji Fukatsu

IPC: A61K31/40 ,  A61K31/381 ,  A61K31/34 ,  C07D333/22 ,  C07D207/30

CPC classification number: C07D307/42 ,  C07D307/38 ,  C07D307/54 ,  C07D307/68 ,  C07D307/79 ,  C07D405/12 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12

Abstract: The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or —S(O)n— (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O)m—, —C(═O)—N(R3)— or —N(R3)—C(═O)— (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

Abstract translation: 本发明提供由式（I）表示的化合物：[其中R是任选取代的烃基或任选取代的杂环基，p是0,1或2，当p是2时，每个R可以相同 或不同的R 1是氢原子或任选取代的烃基，R 2是任选取代的芳族基团，环A是任选取代的单环芳环或任选取代的芳环 取代的双环芳族稠合环，X 1是氧原子或硫原子，X 2是一个键，氧原子或-S（O）n （其中n为0,1或2），Y为键，氧原子，-S（O）m - ， - C（-O）-N（R （O） - （R 3）是氢原子，任选取代的烃 基团或任选取代的杂环基，m为0,1或2），M 1，M 2和M 3可以是 相同或不同，各自独立 键或任选取代的二价脂族烃基，M 4是任选取代的二价脂族烃基]或其盐，其可用作脂质代谢异常的预防和/或治疗剂 ，动脉硬化疾病及其后遗症，糖尿病等。